AbbVie Submits Biologics License Application to U.S. FDA for Etentamig in Relapsed/Refractory Multiple Myeloma

AbbVie announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for etentamig, an investigational second-generation BCMA x CD3 bispecific antibody T-cell engager. The therapy is intended for the treatment of adults living with relapsed or refractory multiple myeloma.

Submission Highlights and Study Context

• Regulatory Filing: Submitted to the U.S. FDA for adult patients with relapsed or refractory multiple myeloma.
• Clinical Basis: Supported by results from the global, Phase 3 CERVINO clinical study comparing etentamig against the investigator's choice of standard available therapies.
• Reported Efficacy: According to the announcement, the study met its dual primary endpoints, showing improvements in overall response rate and progression-free safety metrics compared to standard therapies.

Safety Observations

• Reported Adverse Events: Common treatment-emergent adverse events in the etentamig arm included cytokine release syndrome (CRS), hypogammaglobulinemia, neutropenia, and anemia.
• Administration: Etentamig is designed with an optimized dosing strategy featuring a single step-up dose followed by monthly administration.

Practical Implications and Verification

Patients and healthcare providers can review official company announcements and regulatory filings through the SEC or clinical trial registries such as clinicaltrials.gov (Identifier: NCT06158841) to verify study details and ongoing trial status. Regulatory review timelines and final approval decisions remain subject to FDA evaluation processes.